A new drug called atogepant has been found to be effective in preventing migraines in patients who have failed to respond to other treatments. The drug, developed by Abbvie and sold under the brand name Qulipta, is a calcitonin gene-related peptide inhibitor that reduces the number of days with migraines, and is part of a class of drugs that target a protein responsible for triggering and sustaining migraines. The drug was approved by the US FDA in 2021 to prevent episodic migraines. In a large-scale clinical trial, atogepant was found to reduce the number of days with migraines compared to a placebo. A new study shows that patients who had not responded to other treatments had fewer migraines while taking atogepant than those given a placebo. However, the drug can be expensive, with prices of up to $1,000 per month without insurance. Though some other CGRP drugs cost less, some patients also face difficulty getting their medications covered. The study has yet to be published in a peer-reviewed journal.
Source link
#Migraine #Drug #Atogepant #Works #Difficult #Cases #Study #Finds
